INVESTIGADORES
D`ALESSIO Luciana
congresos y reuniones científicas
Título:
Prevalence of psychiatric disorders and frequency of use of antiepileptic schemes in patients with resistant epilepsy and psychiatric disorders in Argentina
Autor/es:
SCÉVOLA L, FERNANDEZ LIMA M, GIAGANTE B, ODDO S, KOCHEN S, D'ALESSIO L
Reunión:
Congreso; X Congreso Latinoamericano de Epilepsia; 2018
Institución organizadora:
International league against epilepsy (ILAE) y la International Bureau for epilepsy (IBE)
Resumen:
OBJECTIVEThe aim of this study was to determine the prevalence of psychiatric disorders in patients with resistant epilepsy (RE) and to analyze the antiepileptic drugs schemes used in this population. Some antiepileptic drugs are also prescribed for psychiatric disorders, i.e. valproate, lamotrigine and carbamazepine. Nevertheless other like topiramate and phenobarbital may on the contrary induce psychiatric symptoms.METHODS Psychiatric diagnoses and antiepileptic schemes received during psychiatric assessment were retrospectively analyzed in a population of patients consecutively admitted to the Epilepsy Center during 2007-2015. All patients included underwent a neurological and psychiatric assessment protocol (Structured Clinical Interview for DSM IV Axis I disorders, SCID I) and signed the informed consent to participate. Descriptive statistical analysis was determined. Statistical significance was fixed at p ≤ 0.05. RESULTSA total of 251 patients (133 women, 118 men) (age 33.0 ± 11.1 years) with RE were included; 103 (42.0 %) with at least one episode of an affective disorder and 35 (14.3 %) with other non-affective psychiatric disorder. No significant differences were found in antiepileptic schemes among the groups. Only 14.3% received one drug, 54.7% two drugs, and 31% more than two. Patients with psychiatric disorders (n=138) received: carbamazepine 48.6%, valproate 26.1%, levetiracetam 45.7%, lamotrigine 29.7%, topiramate 16 %, phenobarbital 10 %, and 26.1 % received at least one drug with a known negative effect on behavior.CONCLUSIONThe awareness of psychiatric comorbidity may be an important issue to prioritize in deciding medication schemes, avoiding drugs with known negative effects on humor or behavior.